ONCOLOGY INSTITUTE INC/THE
TOINASDAQTrading Snapshot
- Day Range
- $5.10 – $5.23
- 52-Week Range
- $2.32 – $7.05
- Volume
- $3.59B
- Avg Volume
- $4.76B
- Shares Outstanding
- 100.0M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $503M
- Last Q Revenue
- $161M
- P/E Ratio
- -18.3
- P/S Ratio
- 0.9x
- EPS (TTM)
- $-0.04
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1241.0%
Why Investors Own TOI
- ✓High-growth profile — revenue up +25.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ONCOLOGY INSTITUTE INC/THE
TOI
StockOtter · stockotter.spaceAbout ONCOLOGY INSTITUTE INC/THE
The Oncology Institute (TOI) is a specialized healthcare provider delivering a full range of medical oncology services throughout the United States. Its comprehensive offerings include direct physician care, integrated on-site infusion and medication dispensing facilities, and advanced clinical trial management. The institute also provides radiation therapy, specialized outpatient programs for stem cell transplants and transfusions, and robust patient support services. Furthermore, TOI is actively involved in operating palliative care initiatives and overseeing clinical trials. These services are specifically designed to meet the needs of adult and senior cancer patients. The company maintains a significant operational footprint with 67 clinic locations. The Oncology Institute was established in 2007 and is headquartered in Cerritos, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
BlackRock Inc. Buys Shares of 4,749,030 The Oncology Institute, Inc. $TOI
BlackRock Inc. purchased a new position in shares of The Oncology Institute, Inc. (NASDAQ: TOI) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund pur
Head to Head Contrast: RadNet (NASDAQ:RDNT) and Oncology Institute (NASDAQ:TOI)
Oncology Institute (NASDAQ: TOI - Get Free Report) and RadNet (NASDAQ: RDNT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength o
Oncology Institute Q2 Earnings Call Highlights
Oncology Institute NASDAQ: TOI reported second-quarter revenue growth, positive adjusted EBITDA and an expanded pipeline of value-based oncology contracts as the company announced it has rebranded as Starling Oncology.
The Oncology Institute Rebrands as Starling Oncology
CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to “St
The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its second quarter 20
Best Cheap Stocks Under $10 to Buy Now in July
One area of Wall Street that investors might want to start buying are strong, best-in-class, cheap stocks trading under $10 a share in July and throughout the rest of 2026.